The importance of quantifying the adverse effects on healthcare-related quality of life in people with benign gynecologic conditions

Elizabeth L. Wolfe, LaTasha B. Craig
In: F&S Reports · 2024 · vol. 5(2) , pp. 138–139 · doi:10.1016/j.xfre.2024.03.003 · PMID:38983723 · PMC11228797 · W4393226702
editorial OA: gold CC0 ⤵ 1 in-corpus citation
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-13 ⓘ

This review highlights the need to quantify adverse effects on healthcare-related quality of life for individuals diagnosed with benign gynecologic conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-13 · read from full text ⓘ

This paper argues for quantifying adverse effects on healthcare-related quality of life among people with benign gynecologic conditions, emphasizing the importance of patient-centered outcomes in evaluating gynecologic health impacts. It discusses the need to assess harms in terms of quality of life rather than focusing only on clinical endpoints, and it reviews considerations relevant to measurement approaches. The paper’s limitation is that it is not presented as original empirical research using a specific study cohort, but as a perspective/editorial-type discussion of outcome quantification. Relevance to endometriosis: endometriosis and adenomyosis are within the broader category of benign gynecologic conditions where quality-of-life impact measurement is highlighted, though the paper does not describe a study population of endometriosis or adenomyosis patients.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 771 characters · extracted from pmc-nxml · 2 sections · click to expand

Credit

Elizabeth L. Wolfe: Writing – original draft. LaTasha B. Craig: Writing – review & editing.

Coi Statement

E.L.W. has nothing to disclose. L.B.C. reports funding from Oklahoma Shared Clinical and Translational Resource Institute NIGMS U54GM104938, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH/NICHD, Presbyterian Health Foundation, OU College of Medicine Alumni Association; honoraria and travel support from Ferring Pharmaceuticals; planned and pending patent: methods and compositions for treating diseases and conditions associated with gonadotropin-releasing hormone receptor." (Application: February 23, 2018); and a leadership role in the American Board of Obstetrics and Gynecology division of Reproductive Endocrinology & Infertility.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (1)

References (6)

Cited by (1)

Source provenance

europepmc
last seen: 2026-06-21T06:12:49.409960+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK